Osteoporosis

ClinicalJuly 26, 2026

Clinical Trial on Abaloparatide's Impact on Bone Quality in Osteoporotic Patients

A clinical trial is assessing the efficacy of abaloparatide in improving bone density and reducing postoperative complications in osteoporotic patients undergoing spinal surgery.

Companies

Assets

Recent signals(9)

FDA Accepts Supplemental Application for TYMLOS (Abaloparatide)

FDA Accepts Supplement Application for Teriparatide by ALMAJECT

FDA Accepts Supplemental Application for FORTEO (Teriparatide) by Lilly

FDA Accepts Supplemental Application for BONSITY (Teriparatide)

Aurobindo Pharma's Alendronate Sodium Supplement Application Approved by FDA

Clinical Trial on Abaloparatide's Impact on Bone Quality in Osteoporotic Patients

Study on Resistance Training Intensity for Osteoporosis Management

FDA Submission Update for Prolia (Denosumab) by Amgen

FDA Grants AP Status for Teva's Risedronate Sodium Supplement

Upcoming catalysts

Indications

Get signals before the market moves